Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | AOC1 | P19801 | 3/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KMT5B | Q4FZB7 | 2/20 | 0.41 |
| ▸ | KMT5C | Q86Y97 | 2/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23954467 | 1.00 | KDM4E (0.64) | KDM4EGAAMAPTAOC1AOC3 | |
| SCHEMBL19851113 | 1.00 | KDM4E (0.64) | KDM4EGAAMAPTAOC1AOC3 | |
| SCHEMBL13054216 | 1.00 | KDM4E (0.64) | KDM4EGAAMAPTAOC1AOC3 | |
| SCHEMBL15221623 | 0.91 | KDM4E (0.50) | KDM4EGAAMAPTAOC1AOC3 | |
| SCHEMBL880536 | 0.85 | KDM4E (0.48) | KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL12537719 | 0.83 | HRH3 (0.51) | KDM4EGAAMAPTBACE1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL12469771 | 0.82 | HRH3 (0.50) | KDM4EGAAMAPTBACE1ALDH1A1 | |
| SCHEMBL5778944 | 0.79 | KDM4E (0.55) | KDM4EGAAMAPTALDH1A1L3MBTL1 | |
| SCHEMBL21093636 | 0.79 | KDM4E (0.55) | KDM4EGAAMAPTALDH1A1L3MBTL1 | |
| SCHEMBL19851082 | 0.79 | KDM4E (0.55) | KDM4EGAAMAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495362-B1 | IMIDAZOPYRIDINE THIOGLYCOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | UNIV SHANDONG (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10399978-B2 | Imidazopyridine thioglycolic acid derivatives as potent inhibitors of human urate transporter 1 | SHANDONG UNIVERSITY (CN) | 2019-09-03 | — | — | US | disclosed |
| US-20190225606-A1 | Novel Imidazopyridine Thioglycolic Acid Derivatives as Potent Inhibitors of Human Urate Transporter 1 | SHANDONG UNIVERSITY (CN) | 2019-07-25 | — | — | US | disclosed |
| WO-2018023851-A1 | IMIDAZOPYRIDINE THIOGLYCOLIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 山东大学 | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225606-A1 | Novel Imidazopyridine Thioglycolic Acid Derivatives as Potent Inhibitors of Human Urate Transporter 1 | SLC29A1, SLC28A1, SLC5A1 | KDM4E 4243/4885GAA 375/4885MAPT 2058/4885 |
| US-10399978-B2 | Imidazopyridine thioglycolic acid derivatives as potent inhibitors of human urate transporter 1 | SLC29A1, SLC28A1, SLC5A1 | KDM4E 4231/4885GAA 371/4885MAPT 1810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.